{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:00:57Z","timestamp":1762376457757},"reference-count":40,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCP"],"published-print":{"date-parts":[[2019,10,25]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Antipsychotic drugs are the cornerstone of schizophrenia treatment and are also indicated for other psychotic and mood disorders. Different antipsychotic drugs and their formulations are available, though liquid forms have been overlooked.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Herein the added value of liquid antipsychotics is reviewed, with a focus on the recently introduced liquid quetiapine, a frequently used antipsychotic.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Liquid antipsychotics are easily administrated via the preferable oral route, while compliance under supervised administration is transparent. Liquid forms could be preferred in patients with swallowing difficulties, which are common in elderly patients and often concealed. In this population, the availability of liquid antipsychotics could prevent errors in medication administration, which could possibly render caregivers labile to any harm caused to the patient. Aspiration, however, remains a risk with liquid formulations. Common errors in medication administration are the omission of treatment and alteration of solid oral formulations. Regarding quetiapine, omission of treatment could be associated with non-adherence as well as discontinuation symptoms, while alteration of extended release formulation could alter its pharmacokinetics. Mildly agitated and cooperative patients are another target population of liquid antipsychotics, which can induce fast sedation avoiding involuntary intramuscular injections. The combination of sedative properties and low incidence of extrapyramidal symptoms makes liquid quetiapine a valuable option for these patients, yet the current evidence is limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>The liquid form of quetiapine can facilitate pharmacotherapy of schizophrenia and can be defined as value added medicine bringing key benefits not only to the patients and caregivers but also to the health care system.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1574884713666181102145236","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T11:37:08Z","timestamp":1541158628000},"page":"101-107","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Added Value of Liquid Antipsychotics: The Case of Quetiapine"],"prefix":"10.2174","volume":"14","author":[{"given":"Georgios","family":"Papazisis","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyridon","family":"Siafis","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/bmb\/ldv017","volume":"114","author":"Lally J.","year":"2015","unstructured":"Lally J.; MacCabe J.H.; Antipsychotic medication in schizophrenia: a review. Br Med Bull 2015,114(1),169-179","journal-title":"Br Med Bull"},{"key":"ref=2","first-page":"27","author":"Weiden P.J.","year":"2006","unstructured":"Weiden P.J.; Switching in the era of atypical antipsychotics. An updated review. Postgrad Med 2006(Spec No),27-44","journal-title":"Postgrad Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/PROM.S42735","volume":"5","author":"Haddad P.M.","year":"2014","unstructured":"Haddad P.M.; Brain C.; Scott J.; Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas 2014,5,43-62","journal-title":"Patient Relat Outcome Meas"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.pnpbp.2006.03.031","volume":"30","author":"Keith S.","year":"2006","unstructured":"Keith S.; Advances in psychotropic formulations. Prog Neuropsychopharmacol Biol Psychiatry 2006,30(6),996-1008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1017\/S1461145710001380","volume":"14","author":"Leucht S.","year":"2011","unstructured":"Leucht S.; Heres S.; Kissling W.; Davis J.M.; Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol 2011,14(2),269-284","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=6","year":"Oct 2016","unstructured":"Guidelines on Choice and Selection of Antipsychotics for the Management of Psychosis and Schizophrenia in Adults NHSOct 2016","journal-title":"Guidelines on Choice and Selection of Antipsychotics for the Management of Psychosis and Schizophrenia in Adults"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"126","DOI":"10.12968\/bjmh.2013.2.3.126","volume":"2","author":"Mutsatsa S.","year":"2013","unstructured":"Mutsatsa S.; Bressington D.; Oral liquid antipsychotic formula-tion in the treatment of psychosis. Br J Mental Health Nurs 2013,2(3),126-127","journal-title":"Br J Mental Health Nurs"},{"key":"ref=8","year":"2017","unstructured":"Time to Adjust the HTA Decision Frameworks Value Added Medicines2017","journal-title":"Time to Adjust the HTA Decision Frameworks"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1038\/sj.npp.1301646","volume":"33","author":"Jensen N.H.","year":"2008","unstructured":"Jensen N.H.; Rodriguiz R.M.; Caron M.G.; Wetsel W.C.; Rothman R.B.; Roth B.L.; N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine\u2019s antidepressant activity. Neuropsychopharmacology 2008,33(10),2303-2312","journal-title":"Neuropsychopharmacology"},{"key":"ref=10","unstructured":"straZenecaUK. Seroquel 25 mg film-coated tablets-Summary of Product Characteristics (SPC) - (eMC) 2016 [Available from:"},{"key":"ref=11","unstructured":"AstraZenecaUK. Seroquel XL 50 mg prolonged-release tab-lets- Summary of Product Characteristics (SPC) - (eMC) 2016 [Available from:"},{"key":"ref=12","unstructured":"FDA. SEROQUEL (quetiapine fumarate): Highlights of pre-scribing information. 2013 [Available from:"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1517\/14740338.2014.935761","volume":"13","author":"Werner F.M.","year":"2014","unstructured":"Werner F.M.; Cove\u00f1as R.; Safety of antipsychotic drugs: focus on therapeutic and adverse effects. Expert Opin Drug Saf 2014,13(8),1031-1042","journal-title":"Expert Opin Drug Saf"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3928\/02793695-20130709-01","volume":"51","author":"Carney A.C.","year":"2013","unstructured":"Carney A.C.; Efficacy of quetiapine off-label uses: data synthesis. J Psychosoc Nurs Ment Health Serv 2013,51(8),11-18","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"key":"ref=15","unstructured":"RosemontPharmaceuticals. Quetiapine Rosemont 20mg\/ml Oral Suspension-Summary of Product Characteristics (SPC) - (eMC) 2017 [Available from:"},{"key":"ref=16","unstructured":"NHS Choices [Available from:"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ijpharm.2012.04.022","volume":"430","author":"Stegemann S.","year":"2012","unstructured":"Stegemann S.; Gosch M.; Breitkreutz J.; Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy. Int J Pharm 2012,430(1-2),197-206","journal-title":"Int J Pharm"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1007\/s11096-013-9836-2","volume":"35","author":"Marquis J.","year":"2013","unstructured":"Marquis J.; Schneider M.P.; Payot V.; Swallowing difficulties with oral drugs among polypharmacy patients attending community pharmacies. Int J Clin Pharm 2013,35(6),1130-1136","journal-title":"Int J Clin Pharm"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.4155\/tde.11.32","volume":"2","author":"Llorca P.M.","year":"2011","unstructured":"Llorca P.M.; Discussion of prevalence and management of discomfort when swallowing pills: orodispersible tablets expand treatment options in patients with depression. Ther Deliv 2011,2(5),611-622","journal-title":"Ther Deliv"},{"key":"ref=20","first-page":"411","volume":"15","author":"Strachan I.","year":"2005","unstructured":"Strachan I.; Greener M.; Medication-related swallowing diffi-culties may be more common than we realise. Pharm Pract (Granada) 2005,15(10),411-414","journal-title":"Pharm Pract (Granada)"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00455-017-9802-6","volume":"32","author":"Kulkarni D.P.","year":"2017","unstructured":"Kulkarni D.P.; Kamath V.D.; Stewart J.T.; Swallowing Disorders in Schizophrenia. Dysphagia 2017,32(4),467-471","journal-title":"Dysphagia"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1097\/MEG.0000000000000983","volume":"29","author":"Miarons Font M.","year":"2017","unstructured":"Miarons Font M.; Rofes Salsench L.; Antipsychotic medication and oropharyngeal dysphagia: systematic review. Eur J Gastroenterol Hepatol 2017,29(12),1332-1339","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"504","DOI":"10.12968\/npre.2014.12.10.504","volume":"12","author":"Stone M.","year":"2014","unstructured":"Stone M.; Prescribing in patients with dysphagia. Nurse Pre-scribing 2014,12(10),504-507","journal-title":"Nurse Pre-scribing"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"Leucht S.","year":"2013","unstructured":"Leucht S.; Cipriani A.; Spineli L.; Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013,382(9896),951-962","journal-title":"Lancet"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ijpharm.2016.02.036","volume":"512","author":"Serrano Santos J.M.","year":"2016","unstructured":"Serrano Santos J.M.; Poland F.; Wright D.; Longmore T.; Medicines administration for residents with dysphagia in care homes: A small scale observational study to improve practice. Int J Pharm 2016,512(2),416-421","journal-title":"Int J Pharm"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/JCP.0000000000000814","volume":"38","author":"Chiappini S.","year":"2018","unstructured":"Chiappini S.; Schifano F.; Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency\/European Medicines Agency Adverse Drug Reactions\u2019 Database. J Clin Psychopharmacol 2018,38(1),72-79","journal-title":"J Clin Psychopharmacol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1017\/S1041610209991669","volume":"22","author":"Haw C.","year":"2010","unstructured":"Haw C.; Stubbs J.; Administration of medicines in food and drink: a study of older inpatients with severe mental illness. Int Psychogeriatr 2010,22(3),409-416","journal-title":"Int Psychogeriatr"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2147\/CIA.S121905","volume":"12","author":"Logrippo S.","year":"2017","unstructured":"Logrippo S.; Ricci G.; Sestili M.; Oral drug therapy in elderly with dysphagia: between a rock and a hard place! Clin Interv Aging 2017,12,241-251","journal-title":"Clin Interv Aging"},{"key":"ref=29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193683","volume":"13","author":"Thong M.Y.","year":"2018","unstructured":"Thong M.Y.; Manrique Y.J.; Steadman K.J.; Drug loss while crushing tablets: Comparison of 24 tablet crushing devices. PLoS One 2018,13(3)","journal-title":"PLoS One"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.annemergmed.2008.03.016","volume":"52","author":"Ngo A.","year":"2008","unstructured":"Ngo A.; Ciranni M.; Olson K.R.; Acute quetiapine overdose in adults: a 5-year retrospective case series. Ann Emerg Med 2008,52(5),541-547","journal-title":"Ann Emerg Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ijpharm.2012.12.038","volume":"443","author":"Salmon D.","year":"2013","unstructured":"Salmon D.; Pont E.; Chevallard H.; Pharmaceutical and safety considerations of tablet crushing in patients undergoing enteral intubation. Int J Pharm 2013,443(1-2),146-153","journal-title":"Int J Pharm"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1007\/s12603-017-0886-3","volume":"21","author":"Fodil M.","year":"2017","unstructured":"Fodil M.; Nghiem D.; Colas M.; Assessment of Clinical Practices for Crushing Medication in Geriatric Units. J Nutr Health Aging 2017,21(8),904-908","journal-title":"J Nutr Health Aging"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1111\/j.1365-2648.2011.05700.x","volume":"67","author":"Kelly J.","year":"2011","unstructured":"Kelly J.; Wright D.; Wood J.; Medicine administration errors in patients with dysphagia in secondary care: a multi-centre observational study. J Adv Nurs 2011,67(12),2615-2627","journal-title":"J Adv Nurs"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ijpharm.2016.03.007","volume":"512","author":"Liu F.","year":"2016","unstructured":"Liu F.; Ghaffur A.; Bains J.; Hamdy S.; Acceptability of oral solid medicines in older adults with and without dysphagia: A nested pilot validation questionnaire based observational study. Int J Pharm 2016,512(2),374-381","journal-title":"Int J Pharm"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1001\/archotol.131.11.970","volume":"131","author":"Carnaby-Mann G.","year":"2005","unstructured":"Carnaby-Mann G.; Crary M.; Pill swallowing by adults with dysphagia. Arch Otolaryngol Head Neck Surg 2005,131(11),970-975","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1007\/s40265-014-0297-2","volume":"74","author":"Liu F.","year":"2014","unstructured":"Liu F.; Ranmal S.; Batchelor H.K.; Patient-centred pharmaceutical design to improve acceptability of medicines: similarities and differences in paediatric and geriatric populations. Drugs 2014,74(16),1871-1889","journal-title":"Drugs"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/hup.2535","volume":"31","author":"Dundar Y.","year":"2016","unstructured":"Dundar Y.; Greenhalgh J.; Richardson M.; Dwan K.; Pharmacological treatment of acute agitation associated with psychotic and bipolar disorder: a systematic review and meta-analysis. Hum Psychopharmacol 2016,31(4),268-285","journal-title":"Hum Psychopharmacol"},{"key":"ref=38","author":"Garriga M","unstructured":"Garriga M; Pacchiarotti I; Kasper S; Assessment and management of agitation in psychiatry: Expert consensus. The world journal of biological psychiatry: the official journal of the World Federation of Societies of Biological Psychiatry. 2016; 17(2): 86- 128."},{"key":"ref=39","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2017.1264717","volume":"5","author":"Toumi M.","year":"2016","unstructured":"Toumi M.; R\u00e9muzat C.; Value added medicines: what value repurposed medicines might bring to society? J Mark Access Health Policy 2016,5(1)","journal-title":"J Mark Access Health Policy"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nature11691","volume":"492","author":"Besnard J.","year":"2012","unstructured":"Besnard J.; Ruda G.F.; Setola V.; Automated design of ligands to polypharmacological profiles. Nature 2012,492(7428),215-220","journal-title":"Nature"}],"container-title":["Current Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/166986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T14:32:49Z","timestamp":1605364369000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/166986\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,10,25]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574884713666181102145236","relation":{},"ISSN":["1574-8847"],"issn-type":[{"value":"1574-8847","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,25]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-08-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}